Kevin Bugin
Kevin Bugin works for the FDA in the Office of New Drugs as the Director of Special Programs, leading various internally driven initiatives for the enhancement of the new drugs regulatory program. Prior to joining the FDA, Kevin Bugin worked in both industry and government in multiple areas of clinical research and development, such as regulatory affairs, safety and pharmacovigilance, technology transfer, and basic molecular biology research.
×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Americas
-
Rear Admiral Richardae Araojo •
-
Robyn Bent, MS, RN •
-
Kevin Bugin •
-
Namandjé Bumpus •
-
Ashley Boam, MS •
-
Diane Bruce, PharmD, RAC •
-
Suranjan De •
-
Michelle Campbell •
-
Ethan Chen •
-
John Concato •
-
Jacqueline Corrigan-Curay, JD, MD •
-
Christy Cottrell •
-
Selena Daniels, PharmD, PhD, MS •
-
Khair ElZarrad •
-
Ron Fitzmartin, PhD, MBA •
-
Dionna Green •
-
Richard Forshee, PhD •
-
Andrea Fristedt •
-
Cheryl Grandinetti, PharmD •
-
Karen Hicks •
-
Sarah Ibrahim •
-
Xianghong (Emily) Jing •
-
Michael Kopcha, PhD, RPh •
-
Jung Lee •
-
Claudia Manzo •
-
Peter Marks •
-
Janet Maynard •
-
Hilary Marston •
-
Ann Meeker-O'Connell, MS •
-
Monica Morell, PhD •
-
Tina Morrison •
-
Theresa Mullin, PhD •
-
Monica Munoz •
-
Iilun Murphy •
-
Martha Nguyen •
-
Steven Oh, PhD •
-
Lee Pai-Scherf •
-
Y. Veronica Pei •
-
Ana Pineda Zavaleta, MSc •
-
Andrew Potter •
-
Dionne Price, PhD •
-
Scott Proestel, MD •
-
Francisca Reyes-Turcu •
-
Stacey Ricci •
-
Leyla Sahin •
-
Norman Robert Schmuff, PhD •
-
Kimberly Schultz, PhD •
-
Haley Seymour, MS •
-
Mary Ann Slack •
-
Peter Stein •
-
Mary Thanh Hai, MD •
-
Julia Tierney •
-
Melissa Torres •
-
Stelios Tsinontides •
-
Katherine Tyner •
-
John Weiner, JD •
-
Celia Witten •